Cosette Pharmaceuticals Acquires Vyleesi from Palatin Technologies

January 3, 2024

Cosette Pharmaceuticals, a U.S. specialty pharmaceutical company backed by Avista Healthcare Partners, has acquired the Vyleesi (bremelanotide) product and related intellectual property from Palatin Technologies. The deal transfers five Orange Book-listed patents (protection through 2041) and aims to expand Cosette’s women's health portfolio while ensuring continued patient access during the transition.

Buyers
Cosette Pharmaceuticals, Inc., Avista Healthcare Partners
Targets
Vyleesi (bremelanotide injection)
Sellers
Palatin Technologies, Inc.
Industry
Pharmaceuticals
Location
New Jersey, United States
Transaction Type
Divestiture

Explore More

Build a buyer list for your deal

Find active buyers from recent acquisition patterns and move straight into outreach.